Cell line | AKT | ERK1/2 | RB | RPS6 |
|---|
BT474 | - |
TE
|
E
|
TP
|
HCC1954 |
E
|
TE
|
E
| - |
SKBR3 | PTE |
TE
|
TE
|
TE
|
- The table summarises the optimal drug treatments for the long-term data, leading to inactive AKT, ERK1/2, RB and RPS6, respectively. In case of a significant (p-value < 0.05) combined influence of both, drug treatment and time, on the protein signal intensity, a Wilcoxon rank sum test was conducted for the measurements at time point 30 hours, testing for significantly (p-value < 0.05) smaller intensity values under the drug treatment compared to the control measurement. The drug treatment with the smallest p-value was considered as the optimal inhibitor. No inferred significant positive drug effect is denoted by ‘-’. The therapeutics erlotinib, trastuzumab and pertuzumab are abbreviated by their first letters. More than one letter denotes drug combinations. The column Cell line holds the cell lines under consideration. The columns AKT, ERK1/2, RB and RPS6 hold the optimal drug combinations for each target. If those were confirmed by the attractor states (0) of perturbation simulations, they are printed in bold.
